Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | RARA | P10276 | 6/20 | 0.67 |
| ▸ | RXRA | P19793 | 5/20 | 0.67 |
| ▸ | RARB | P10826 | 4/20 | 0.67 |
| ▸ | RARG | P13631 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | RXRB | P28702 | 2/20 | 0.67 |
| ▸ | RXRG | P48443 | 2/20 | 0.67 |
| ▸ | RORC | P51449 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | GMNN | O75496 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23356521 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1718341 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1718339 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL3500196 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1765991 | 0.90 | MAPT (0.82) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1765989 | 0.90 | MAPT (0.82) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL21140941 | 0.89 | ALDH1A1 (0.80) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL1498298 | 0.88 | MAPT (0.79) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL13903879 | 0.87 | MAPT (0.77) | ALDH1A1MAPTSMN1; SMN2RARARXRA | |
| SCHEMBL3701619 | 0.87 | ALDH1A1 (0.77) | ALDH1A1MAPTSMN1; SMN2RARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3967299-B1 | PKC ACTIVATORS AND COMBINATIONS THEREOF FOR TREATING ALZHEIMER DISEASE | COGNITIVE RES ENTERPRISES INC (US) | 2025-06-18 | — | — | EP | claimed |
| EP-3967299-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | Cognitive Research Enterprises, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| US-10821079-B2 | PKC activators and combinations thereof | COGNITIVE RESEARCH ENTERPRISES, INC. (US) | 2020-11-03 | — | — | US | claimed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | claimed |
| EP-2776018-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | Blanchette Rockefeller Neurosciences Institute (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013071282-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2013-05-16 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-3967299-B1 | PKC ACTIVATORS AND COMBINATIONS THEREOF FOR TREATING ALZHEIMER DISEASE | COGNITIVE RES ENTERPRISES INC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-3967299-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | Cognitive Research Enterprises, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3386947-B1 | METHOD FOR PRODUCING N-RETINOYLAMINOALKANE SULFONIC ACID | OASMIA PHARMACEUTICAL AB (SE) | 2021-05-19 | — | — | EP | disclosed |
| US-10821079-B2 | PKC activators and combinations thereof | COGNITIVE RESEARCH ENTERPRISES, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| EP-2776018-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | Blanchette Rockefeller Neurosciences Institute (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071282-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821079-B2 | PKC activators and combinations thereof | PRKCH, PRKCB, PRKCA | ALDH1A1 4622/4885MAPT 4095/4885SMN1; SMN2 3090/4885 |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | PRKCH, PRKCB, PRKCA | ALDH1A1 4622/4885MAPT 4095/4885SMN1; SMN2 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.